New therapy for aggressive blood cancer discovered

Acute myeloid leukemia (AML) is the most common form of acute leukemia. It is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells.

Only twenty-five percent of all AML patients survive five years beyond the initial diagnosis. Therefore there is an urgent need to deepen the knowledge about this form of blood cancer and to develop new therapeutic approaches.

A study carried out by researchers at the Ludwig Boltzmann Institute for Cancer Research, the Vetmeduni Vienna and the Medical University Vienna has now identified a possible approach for the treatment of AML patients, which carry a mutated, oncogenic isoform of the protein C/EBPα.

According to the results published in Leukemia, the interaction of the mutated protein with an epigenetic regulator, the so-called MLL1 complex, represents a specific vulnerability of AML cells with CEBPA mutations. If the MLL1 complex was functionally inhibited, AML cells underwent cell death. Via targeted inhibition of MLL1, the cancer-associated block in normal blood cell maturation could potentially be released in affected AML patients.

Focusing on the malignant isoform of an important factor in blood development

The transcription factor CCAAT/enhancer binding protein alpha C/EBPα, is an important regulator of blood development, as it controls critical steps in the maturation of blood cells. However, in ten to fifteen percent of all AML patients, the CEBPA gene harbors mutations that prevent the formation of the correct protein isoform.

“In AML patients, most mutations occur in the N-terminal part of the CEBPA gene. This leads to the production of a shortened C/EBPα protein, the isoform p30, which is responsible for keeping cells in an immature state and can thus trigger leukemia”, explains Luisa Schmidt, the first author of the study, whose work was funded by a fellowship from the Austrian Academy of Sciences (DOC).

The oncogenic protein variant C/EBPα p30, which is over-produced as a result of the mutation, makes use of epigenetic mechanisms to control gene expression in leukemia cells.

Oncogenic protein variant requires functional epigenetic regulator complex

It is known that epigenetic processes can control the expression of genes. It has also been shown that the C/EBPα p30 isoform uses these processes to regulate gene expression patterns of leukemia cells. This oncogenic variant binds to the promoters of certain genes and recruits chromatin-modifying complexes, including histone methyltransferases. One of these interaction partners is the MLL1 complex, which is required for transcriptional activation and has been shown to be critical for the maintenance of hematopoietic stem and progenitor cells.

“Using a combination of biochemical, genetic and pharmacological approaches, we have now been able to show that the MLL1 histone methyltransferase complex is a critical vulnerability in AML with CEBPA mutations”, says Schmidt. Global studies of protein-DNA interactions showed that the binding pattern of the C/EBPα p30 isoform strongly overlap with that of MLL1. This suggests an interaction and cooperation of these two factors, which was confirmed by additional biochemical experiments.

Targeting of the MLL1 complex function by CRISPR/Cas9-mediated mutagenesis of the MLL1 protein further demonstrated that the growth of AML cells with CEBPA mutations depends on the correct assembly and chromatin anchoring of the MLL1 complex.

In accordance with these results, AML cells with CEBPA mutations were highly sensitive to pharmacological inhibition of the MLL1 complex by specific small-molecule inhibitors.

MLL1 complex inhibition impaired proliferation and caused death of AML cells with CEBPA mutations. Further, treatment of CEBPA-mutated AML cells with MLL1 complex inhibitors reversed the differentiation block of cancer cells and restored normal maturation of blood cells.

Florian Grebien, head of the study at the Ludwig Boltzmann Institute for Cancer Research and at Vetmeduni Vienna, is optimistic, “The result that C/EBPα p30 requires a functional MLL1 complex to control oncogenic gene expression programs reveals a high sensitivity of CEBPA- mutated AML to the inhibition of the MLL1 complex function. These results broaden our understanding of CEBPA-mutated AML and identify the MLL1 complex as a potential therapeutic target for this disease”.

About the University of Veterinary Medicine, Vienna

The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. The Vetmeduni Vienna plays in the global top league: in 2018, it occupies the excellent place 6 in the world-wide Shanghai University veterinary in the subject “Veterinary Science”. http://www.vetmeduni.ac.at

Released by:
Georg Mair
Science Communication / Corporate Communications
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-1165
E georg.mair@vetmeduni.ac.at

Florian Grebien
Institute for Medical Biochemistry
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-4200
E Florian.Grebien@vetmeduni.ac.at

and

Luisa Schmidt
Institute for Medical Biochemistry
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-4202
E schmidtl@staff.vetmeduni.ac.at

The Article “CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex” from Luisa Schmidt, Elizabeth Heyes, Lisa Scheiblecker, Thomas Eder, Giacomo Volpe, Jon Frampton, Claus Nerlov, Peter Valent, Jolanta Grembecka and Florian Grebien was published in Leukemia. https://www.nature.com/articles/s41375-019-0382-3

https://www.vetmeduni.ac.at/en/infoservice/press-releases/press-releases-2019/ne…